» Articles » PMID: 36726589

Skeletal Diseases Caused by Mutations in Show Aberrant Differentiation of Skeletal Progenitors Due to Dysregulation of DEPTOR

Overview
Specialty Cell Biology
Date 2023 Feb 2
PMID 36726589
Authors
Affiliations
Soon will be listed here.
Abstract

Alterations in the balance between skeletogenesis and adipogenesis is a pathogenic feature in multiple skeletal disorders. Clinically, enhanced bone marrow adiposity in bones impairs mobility and increases fracture risk, reducing the quality of life of patients. The molecular mechanism that underlies the balance between skeletogenesis and adipogenesis is not completely understood but alterations in skeletal progenitor cells' differentiation pathway plays a key role. We recently demonstrated that parathyroid hormone (PTH)/PTH-related peptide (PTHrP) control the levels of DEPTOR, an inhibitor of the mechanistic target of rapamycin (mTOR), and that DEPTOR levels are altered in different skeletal diseases. Here, we show that mutations in the PTH receptor-1 (PTH1R) alter the differentiation of skeletal progenitors in two different skeletal genetic disorders and lead to accumulation of fat or cartilage in bones. Mechanistically, DEPTOR controls the subcellular localization of TAZ (transcriptional co-activator with a PDZ-binding domain), a transcriptional regulator that governs skeletal stem cells differentiation into either bone and fat. We show that DEPTOR regulation of TAZ localization is achieved through the control of Dishevelled2 (DVL2) phosphorylation. Depending on nutrient availability, DEPTOR directly interacts with PTH1R to regulate PTH/PTHrP signaling or it forms a complex with TAZ, to prevent its translocation to the nucleus and therefore inhibit its transcriptional activity. Our data point DEPTOR as a key molecule in skeletal progenitor differentiation; its dysregulation under pathologic conditions results in aberrant bone/fat balance.

Citing Articles

The Crosstalk Between Cartilage and Bone in Skeletal Growth.

Hernandez-Garcia F, Fernandez-Iglesias A, Rodriguez Suarez J, Gil Pena H, Lopez J, Perez R Biomedicines. 2025; 12(12.

PMID: 39767569 PMC: 11727353. DOI: 10.3390/biomedicines12122662.


Renal osteodystrophy: something old, something new, something needed.

David V, Salusky I, Malluche H, Nickolas T Curr Opin Nephrol Hypertens. 2023; 32(6):559-564.

PMID: 37753646 PMC: 10539012. DOI: 10.1097/MNH.0000000000000918.


Look who's TORking: mTOR-mediated integration of cell status and external signals during limb development and endochondral bone growth.

Ho Hng C, Khaladkar A, Rosello-Diez A Front Cell Dev Biol. 2023; 11:1153473.

PMID: 37152288 PMC: 10154674. DOI: 10.3389/fcell.2023.1153473.

References
1.
Chan G, Deckelbaum R, Bolivar I, Goltzman D, Karaplis A . PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology. 2001; 142(11):4900-9. DOI: 10.1210/endo.142.11.8515. View

2.
Yu B, Huo L, Liu Y, Deng P, Szymanski J, Li J . PGC-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing TAZ. Cell Stem Cell. 2018; 23(4):615-623. PMC: 6613582. DOI: 10.1016/j.stem.2018.09.001. View

3.
Hossain Z, Mohamed Ali S, Ko H, Xu J, Peng Ng C, Guo K . Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A. 2007; 104(5):1631-6. PMC: 1785239. DOI: 10.1073/pnas.0605266104. View

4.
Veldhuis-Vlug A, Rosen C . Mechanisms of marrow adiposity and its implications for skeletal health. Metabolism. 2017; 67:106-114. PMC: 5325679. DOI: 10.1016/j.metabol.2016.11.013. View

5.
Schipani E, Lanske B, Hunzelman J, Luz A, Kovacs C, Lee K . Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci U S A. 1998; 94(25):13689-94. PMC: 28367. DOI: 10.1073/pnas.94.25.13689. View